Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced that Matthew Walsh, Executive
Vice President & Chief Financial Officer, will present at the 26th
Annual Piper Jaffray Healthcare Conference at 10:00 a.m. ET on
Wednesday, December 3, 2014 in New York City.
A live webcast of Catalent’s presentation can be accessed from the
Company’s website at www.catalent.com
and will be available for replay later that day.
About Catalent, Inc.
Catalent, Inc. (NYSE:CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately
8,000 people, including over 1,000 scientists, at nearly 30 facilities
across 5 continents and in fiscal 2014 generated more than $1.8 billion
in annual revenue. Catalent is headquartered in Somerset, N.J. For more
information, please visit www.catalent.com.
Forward-Looking Statements
This release contains both historical and forward-looking statements.
All statements other than statements of historical fact are, or may be
deemed to be, forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements generally can be identified by the use of statements that
include phrases such as “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,”
“would” or other words or phrases with similar meanings. Similarly,
statements that describe our objectives, plans or goals are, or may be,
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Catalent, Inc.’s expectations and
projections. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: participation in
a highly competitive market and increased competition may adversely
affect the business of the Company; demand for the Company’s offerings
which depends in part on the Company’s customers’ research and
development and the clinical and market success of their products;
product and other liability risks that could adversely affect the
Company’s results of operations, financial condition, liquidity and cash
flows; failure to comply with existing and future regulatory
requirements; failure to provide quality offerings to customers could
have an adverse effect on our business and subject the Company to
regulatory actions and costly litigation; problems providing the highly
exacting and complex services or support required; global economic,
political and regulatory risks to the operations of the Company;
inability to enhance existing or introduce new technology or service
offerings in a timely manner; inadequate patents, copyrights, trademarks
and other forms of intellectual property protections; fluctuations in
the costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials; changes
in market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S. dollar
and other foreign currencies; adverse tax legislation initiatives or
challenges to the Company’s tax positions; loss of key personnel; risks
generally associated with information systems; inability to complete any
future acquisitions and other transactions that may complement or expand
the business of the Company or divest of non-strategic businesses or
assets and the Company’s ability to successfully integrate acquired
business and realize anticipated benefits of such acquisitions;
offerings and customers’ products that may infringe on the intellectual
property rights of third parties; environmental, health and safety laws
and regulations, which could increase costs and restrict operations;
labor and employment laws and regulations; additional cash contributions
required to fund the Company’s existing pension plans; substantial
leverage resulting in the limited ability of the Company to raise
additional capital to fund operations and react to changes in the
economy or in the industry, exposure to interest rate risk to the extent
of the Company’s variable rate debt and preventing the Company from
meeting our obligations under our indebtedness. For a more detailed
discussion of these and other factors, see the information under the
caption “Risk Factors” in our 10-K for the fiscal year ended June 30,
2014, filed with the Securities and Exchange Commission. All
forward-looking statements speak only as of the date of this release or
as of the date they are made, and Catalent, Inc. does not undertake to
update any forward-looking statement as a result of new information or
future events or developments except to the extent required by law.
More products. Better treatments. Reliably supplied.™
Investor:
Bertner Advisors, LLC
Monique Kosse, 860-940-0352
Monique.Kosse@BertnerAdvisors.com